Insider · CIK 0001814899
George W. Lloyd
officer
Files at RPRX (Royalty Pharma plc). First filing Nov 21, 2025, latest Dec 19, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $14M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RPRX: Royalty Pharma plc
RPRXOct 9, 2026 · close 56.93
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Royalty Pharma plc | $4.2M 110,000 shares | -100% | +62% from low-6% from high | |
| 55Moderate | Royalty Pharma plc | $4.4M 110,000 shares | -50% | +67% from low-2% from high | |
| 55Moderate | Royalty Pharma plc | $5.2M 135,426 shares | -231% | +63% from low-5% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 17, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2014 G, LLC10b5-1 | -79,346 | $38.57 | $3.1M | 30,654 | Dec 19, 2025 |
| Dec 18, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2014 G, LLC10b5-1 | -30,654 | $38.50 | $1.2M | 0 | Dec 19, 2025 |
| Dec 3, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2014 G, LLC10b5-1 | -110,000 | $39.77 | $4.4M | 110,000 | Dec 5, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC10b5-1 | -47,798 | $38.28 | $1.8M | 10,712 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC10b5-1 | -4,628 | $39.01 | $181k | 6,084 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2020 G, LLC10b5-1 | -47,401 | $38.28 | $1.8M | 4,599 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2020 G, LLC10b5-1 | -4,599 | $39.01 | $179k | 0 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2021 G, LLC10b5-1 | -25,530 | $38.28 | $977k | 2,470 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2021 G, LLC10b5-1 | -2,470 | $39.01 | $96k | 0 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Shares10b5-1 | -2,770 | $38.29 | $106k | 230 | Nov 21, 2025 |
| Nov 19, 2025 | RPRX Royalty Pharma plc | SOpen-market sale Class A Ordinary Shares10b5-1 | -230 | $39.03 | $8,978 | 0 | Nov 21, 2025 |
| Nov 5, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC | +6,168 | $0.00 | $0 | 58,510 | Nov 7, 2025 |
| Aug 6, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC | +3,696 | $0.00 | $0 | 52,342 | Aug 8, 2025 |
| Aug 8, 2025 | RPRX Royalty Pharma plc | GGift LP interests in RPI US Partners 2019, LPderivative | -8,500 | $0.00 | $0 | 0 | Aug 8, 2025 |
| May 16, 2025 | RPRX Royalty Pharma plc | AGrant or award Class E Ordinary Sharesderivativeindirect: See Footnote (1)(2) | +1,944,471 | $0.00 | $0 | 1,944,471 | May 20, 2025 |
| May 8, 2025 | RPRX Royalty Pharma plc | AGrant or award Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC | +48,646 | $0.00 | $0 | 48,646 | May 9, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.